Accepted for Publication: July 11, 2012.
Published Online: October 22, 2012. doi:10.1001/jamaneurol.2013.574
Author Contributions:Study concept and design: McKeon, Pittock, Lennon, and Dalmau. Acquisition of data: McKeon, Martinez-Hernandez, Lancaster, Matsumoto, McEvoy, and Dalmau. Analysis and interpretation of data: McKeon, Martinez-Hernandez, Harvey, Pittock, and Dalmau. Drafting of the manuscript: McKeon and Dalmau. Critical revision of the manuscript for important intellectual content: McKeon, Martinez-Hernandez, Lancaster, Matsumoto, Harvey, McEvoy, Pittock, Lennon, and Dalmau. Statistical analysis: McKeon. Obtained funding: Lancaster, Harvey, and Dalmau. Administrative, technical, and material support: Martinez-Hernandez, Harvey, and Dalmau. Study supervision: McKeon and Dalmau.
Financial Disclosures: Dr McKeon has received research support from the Guthy Jackson Charitable Foundation. Dr Martinez-Hernandez received research grant FI08/00285 from Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III, Spain. Dr Lancaster has received research support from Talecris Biotherapeutics, Lundbeck Inc, and the Dana Foundation. Dr Harvey received grant G0601585 from the Medical Research Council and grant 1966 from Action Medical Research. Dr Pittock is a named inventor on patents (12/678 350 filed 2010 and 12/573 942 filed 2008) that relate to functional aquaporin-4 (AQP4)/neuromyelitis optica (NMO)–IgG assays and NMO-IgG as a cancer marker, and he receives research support from Alexion Pharmaceuticals Inc, the Guthy-Jackson Charitable Foundation, and the National Institutes of Health. Dr Lennon is a named inventor on a patent (7101679 issued 2006) relating to AQP4 antibodies for the diagnosis of NMO and receives royalties for this technology. She is a named inventor on patents (12/678 350 filed 2010 and 12/573 942 filed 2008) related to functional AQP4/NMO-IgG assays and NMO-IgG as a cancer marker and receives research support from the Guthy-Jackson Charitable Foundation and National Institutes of Health. Dr Dalmau is named inventor on patents (6 387 639 and 7 972 796) related to the of Ma2 and NMDAR as autoantibody diagnostic tests and has patents filed for the use of gamma-aminobutyric acid receptor and leucine-rich glioma-inactivated 1 as diagnostic tests. He receives royalties from the editorial board of Up-To-Date and license fee payments from Euroimmun AG. Dr Dalmau receives research support from Euroimmun AG. His current work has been partially funded by the grants RO1NS077851 and RO1MH094741 from the National Institutes of Health and Fundació la Marató TV3 and Fondo de Investigaciones Sanitarias (FIS, PI11/01780)/Fondo Europeo de Desarrollo Regional (FEDER).